Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

@article{Nagashima2005EffectsOT,
  title={Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.},
  author={Kazunori Nagashima and Carlos L{\'o}pez and Daniel Donovan and Colleen Ngai and Nelson Fontanez and Andr{\'e} Bensadoun and Jamila Fruchart-Najib and Steve F Holleran and Jeffrey S. Cohn and Rajasekhar Ramakrishnan and Henry N. Ginsberg},
  journal={The Journal of clinical investigation},
  year={2005},
  volume={115 5},
  pages={1323-32}
}
Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase-mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARgamma agonist that improves… CONTINUE READING